Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY

Multiple Sclerosis Journal Pub Date : 2025-02-10 DOI:10.1177/13524585251316471

Mariano Marrodan, Augusto Sao Avilés, Jordi Río, Álvaro Cobo-Calvo, Victoria Fernández, Agustin Pappolla, Joaquín Castilló, Ángela Vidal-Jordana, Georgina Arrambide, Carmen Tur, Breogán Rodríguez-Acevedo, Ana Zabalza, Neus Mongay-Ochoa, Andreu Vilaseca, Marta Rodriguez, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Cristina Auger, Àlex Rovira, Xavier Montalban, Luciana Midaglia

{"title":"Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.","authors":"Mariano Marrodan, Augusto Sao Avilés, Jordi Río, Álvaro Cobo-Calvo, Victoria Fernández, Agustin Pappolla, Joaquín Castilló, Ángela Vidal-Jordana, Georgina Arrambide, Carmen Tur, Breogán Rodríguez-Acevedo, Ana Zabalza, Neus Mongay-Ochoa, Andreu Vilaseca, Marta Rodriguez, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga, Mar Tintoré, Cristina Auger, Àlex Rovira, Xavier Montalban, Luciana Midaglia","doi":"10.1177/13524585251316471","DOIUrl":null,"url":null,"abstract":"Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and very high-efficacy therapies (HET/vHET) remains unclear.Objective: This study aimed to evaluate the performance of TRSS in patients treated with HET/vHET.Methods: We retrospectively studied MS patients treated with HET/vHET in an MS specialized centre. TRSS, including the Rio Score, modified Rio Score and MAGNIMS score, were applied to assess response to treatment. We evaluated the predictive value of the TRSS on disease activity and disability progression.Results: TRSS effectively predicted disease activity and progression of disability in patients treated with HET/vHET. Patients with high TRSS scores at 12 months post-HET/vHET initiation had a significantly increased risk of relapses, new lesions on magnetic resonance imaging (MRI) scans and progression of disability at 4 years.Discussion: Our findings highlight the importance of personalized treatment strategies in MS. TRSS are valuable tools for monitoring treatment response, guiding clinical decision-making and optimizing patient care.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585251316471"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585251316471","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and very high-efficacy therapies (HET/vHET) remains unclear.

Objective: This study aimed to evaluate the performance of TRSS in patients treated with HET/vHET.

Methods: We retrospectively studied MS patients treated with HET/vHET in an MS specialized centre. TRSS, including the Rio Score, modified Rio Score and MAGNIMS score, were applied to assess response to treatment. We evaluated the predictive value of the TRSS on disease activity and disability progression.

Results: TRSS effectively predicted disease activity and progression of disability in patients treated with HET/vHET. Patients with high TRSS scores at 12 months post-HET/vHET initiation had a significantly increased risk of relapses, new lesions on magnetic resonance imaging (MRI) scans and progression of disability at 4 years.

Discussion: Our findings highlight the importance of personalized treatment strategies in MS. TRSS are valuable tools for monitoring treatment response, guiding clinical decision-making and optimizing patient care.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Multiple Sclerosis Journal 医学-临床神经学

CiteScore

10.90

自引率

6.90%

发文量

186

审稿时长

3-8 weeks

期刊介绍： Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585